PRNewswire

LA JOLLA, Calif., Dec. 5, 2024 /PRNewswire/ — EpicentRx announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for the oncolytic adenovirus-delivered transforming growth factor beta (TGFβ) inhibitor, AdAPT-001, plus the anti-PD-1, nivolumab, or anti-PD

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: